Pirtobrutinib with high-dose chemo and stem cell transplant for relapsed DLBCL
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests adding a targeted drug called pirtobrutinib to a standard high-dose chemotherapy regimen before a stem cell transplant. It aims to improve outcomes for people with diffuse large B-cell lymphoma that has come back or not responded to previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with diffuse large B-cell lymphoma and have had at least two prior treatments, with your disease either partially or fully responding.
- You are between 18 and 70 years old.
- You are generally able to care for yourself (ECOG score 0-2).
- Your blood counts and liver, kidney, and heart function are within acceptable ranges.
- You have not had a prior stem cell transplant using your own cells.
- You do not have active hepatitis B, hepatitis C, or HIV, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (zanubrutinib) combined with a strong chemotherapy regimen (BEAM) before a stem cell transplant. The goal is to see if this combination can help people whose lymphoma has come back or not responded to previous treatments.
This trial tests a new drug called pirtobrutinib combined with standard chemotherapy (R-CHOP) for people with a type of large B-cell lymphoma that hasn't been treated before. The goal is to see if adding this drug helps the treatment work better.
This trial tests a new combination of targeted therapy (pirtobrutinib) with standard chemotherapy (Pola-R-CHP) for people newly diagnosed with a type of large B-cell lymphoma that is not the germinal center B-cell subtype. The goal is to see if adding pirtobrutinib helps the treatment work better.
This trial tests a new targeted therapy (pirtobrutinib) combined with standard chemo-immunotherapy, with or without an extra targeted drug (polatuzumab vedotin), for people whose large B-cell lymphoma has returned or not responded after prior BTK inhibitor treatment. The goal is to see if this combination can help control the cancer.
This trial tests a combination of three drugs—pirtobrutinib, lisaftoclax, and rituximab—for people with relapsed or refractory DLBCL who have already had at least one prior treatment. The goal is to see if this combination can help shrink or control the lymphoma.
This trial tests a new combination: zanubrutinib (a targeted pill) plus standard chemotherapy (R-CHOP) for people newly diagnosed with DLBCL whose cancer cells have high p53 protein levels. The goal is to see if adding this drug helps shrink tumors better than chemotherapy alone.
Hear when a new DLBCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.